ArticlePloS one2026
Machine learning-assisted optimization of a terahertz photonic metamaterial absorber for blood cancer detection.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blood cancer originates in the bone marrow and disrupts the body's normal hematopoietic processes. The rapid progression of this disease highlights the need for accurate and sensitive detection to improve treatment outcomes. Here, we present a novel, compact, multi-resonant terahertz photonic metamaterial absorber for blood cancer detection. The compact structure, with dimensions of 0.41[Formula: see text] × 0.41[Formula: see text] × 0.029[Formula: see text], integrates multiple circular resonators with a rectangular patch, supporting strongly confined resonances that achieve near-unity absorption of 97.6%, 99.9%, and 99.6% at 3.48 THz, 4.95 THz, and 6.01 THz, respectively. The sensing performance was evaluated by introducing an analyte layer representing normal and cancerous blood cells, resulting in remarkable sensitivities of 1.28 THz/RIU, 3.00 THz/RIU, and 2.14 THz/RIU at the three resonance frequencies. The corresponding quality factor (Q-factor) values are 15.03, 20.21, and 24.5, and the figure of merit (FOM) values are 5.54, 12.24, and 8.73 for the three resonance peaks, supporting its reliability in sensing. Moreover, the electric field, magnetic field, and surface current distributions were analysed, and an equivalent circuit model was also developed and validated against the simulated results. Several machine learning models were also employed for design prediction, with Gradient Boosting demonstrating excellent performance and enabling up to a 60% reduction in optimization time. The combination of a multi-band, high-absorption design and ML-assisted approach provides a robust, ultrathin, and high-sensitivity platform, offering a promising route toward next-generation terahertz biophotonic sensors for accurate and sensitive blood cancer detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.